View Profile

Peer Reviewed Papers, Books, Chapters

Year Title Citation Authors Review type Summary Keywords File filename File mime type
1. 2011 Thrombin expression in prostate: a novel finding Cancer Invest. 2011 Jan; 29(1):62-7. PMID:21166500. DOI:10.3109/07357907.2010.535057
2. 2011 Clinical hypothyroidism in a renal cell carcinoma patient treated with sorafenib Clin Adv Hematol Oncol. 2011 Apr; 9(4):335-8. PMID:21558995.
3. 2011 Novel Molecular Targets of Azadirachta indica Associated with Inhibition of Tumor Growth in Prostate Cancer AAPS J. 2011 May 11. [Epub ahead of print] PMID:21560017. DOI:10.1208/s12248-011-9279-4.
4. 2010 Endocrine Manipulations CANCER: Principles and Practice of Oncology 2010. (Book chapter)
5. 2010 New developments in the medical management of prostate cancer Mayo Clin Proc. 2010 Jan; 85(1):77-86. PMID:20042563. PMCID:2800284. DOI:10.4065/mcp.2009.0442.
6. 2010 Exploratory study of a KLK2 polymorphism as a prognostic marker in prostate cancer. Cancer Biomark. 2010; 7(2):101-8. PMID:21178268. DOI:10.3233/CBM-2010-0152.
7. 2010 Multiple urinary bladder masses from metastatic prostate adenocarcinoma Rare Tumors. 2010; 2(4):186-188. DOI:10.4081/rt.2010e65.
8. 2010 Hormonal Therapy in Prostate Cancer Encyclopedia of Cancer 3rd ed. 2010. (Book chapter)
9. 2009 Tissue factor and VEGF expression in prostate carcinoma: a tissue microarray study. Cancer Invest. 2009 May; 27(4):430-4. PMID:19219655. DOI:10.1080/07357900802527247.
10. 2008 Expression of tissue factor in prostate cancer correlates with malignant phenotype Appl Immunohistochem Mol Morphol. 2008 Jan; 16(1):1-6. PMID:18091328. DOI:10.1097/01.pai.0000213157.94804.fc.
11. 2006 Surface-enhanced laser desorption/ionization time-of-flight mass spectrometry (SELDI-TOF MS) for determining prognosis in advanced stage hormone relapsing prostate cancer. Cancer Biomark. 2006; 2(6):249-58. PMID:17264396.
12. 2006 Metastasectomy for isolated bilateral adrenal metastases in hormone-refractory prostate cancer. Clin Adv Hematol Oncol. 2006 Oct; 4(10):754-5; discussion 756-7. PMID:17099632.
13. 2006 Management of solitary palatal metastasis from renal cell carcinoma Nat Clin Pract Urol. 2006 Jul; 3(7):392-6; quiz following 396. PMID:16835627. DOI:10.1038/ncpuro0536
14. 2006 Evaluation of prostate-specific antigen declines for surrogacy in patients treated on SWOG 99-16. J Natl Cancer Inst. 2006 Apr 19; 98(8):516-21.
15. 2006 Evaluation of an adrenal mass in a patient with progressive prostate cancer reveals pheochromocytoma. Int J Urol. 2006 Jun; 13(6):798-800. PMID:16834663. DOI:10.1111/j.1442-2042.2006.01405.x.
16. 2005 Thrombin and thrombin receptor expression in prostate cancer. Prostate. 2005 Oct 21
17. 2005 Stage specific expression of VEGF A and D in prostate cancer Clin Cancer Res. 2005; 11:1-10.
18. 2005 Ocular melanoma versus ocular metastasis: a diagnostic dilemma. Clin Adv Hematol Oncol. 2005 May; 3(5):425-7. PMID:16167017
19. 2005 Orbital metastasis from prostate cancer: an atypical case of neuroendocrine dedifferentiation during progression from hormone-sensitive to refractory stage Clin Prostate Cancer. 2005 Sep; 4(2):134-7. PMID:16197616.
20. 2005 Randomized Phase III Trial of High-Dose Interleukin-2 Versus Subcutaneous Interleukin-2, Interferon in Patients with Metastatic Renal Cell Carcinoma J Clin Oncol. 2005 Sep 1; 23(25):6267-8.
21. 2004 The academic hematology-oncology firm: a model for postgraduate cancer education J Cancer Educ. 2004 Spr; 19(1):45-9. PMID:15059755.
22. 2004 Docetaxel and estramustine compared with mitoxantrone and prednisone for advanced refractory prostate cancer. N Engl J Med. 2004 Oct 7; 351(15):1513-20
23. 2004 COX-2: an inconsistent therapeutic target in prostate cancer Uro Oncology. 2004 Sept/Dec; 4(3/4):113-8.
24. 2003 Role of coagulation and fibrinolytic system in prostate cancer Semin Thromb Hemost. 2003 Jun; 29(3):301-8. PMID:12888934
25. 2003 Prospective study of circulating angiogenic markers in prostate-specific antigen (PSA)-stable and PSA-progressive hormone-sensitive advanced prostate cancer Urology. 2003 Apr; 61(4):765-9. PMID:12670562.
26. 2003 Potential anticancer effects of statins: fact or fiction? Endothelium. 2003; 10(1):49-58. PMID:12699077
27. 2003 Combined endocrine blockade in premenopausal breast cancer: a superior therapeutic option for adjuvant management? J Clin Oncol. 2003 Jun 15; 21(12):2445. PMID:12805351.
28. 2002 Advanced prostate cancer activates coagulation: a controlled study of activation markers of coagulation in ambulatory patients with localized and advanced prostate cancer Blood Coagul Fibrinolysis. 2002 Jan; 13(1):1-5. PMID:11994561
29. 2002 Endothelial dysfunction in antiangiogenesis-associated thrombosis. J Clin Oncol. 2002 Jul 1; 20(13):3042; author reply 3042-3. PMID:12089240.
30. 2000 Use of HFE mutation analysis for hereditary hemochromatosis: the need for physician education in the translation of basic science to clinical practice. South Med J. 2000 May; 93(5):469-71. PMID:10832943
31. 1999 Impact of nutrition on the age related declines in heamatopoiesis Chernoff R. Geriatric nutrition the health professional’s handbook. 2nd ed. Aspen: Jones & Bartlett Publishers; 1999. (Book chapter)
32. Plasma exosomal miRNAs were evaluated for prognosis in an initial set of 44 metastatic renal cell cancer (mRCC) patients by RNA sequencing. Pubmed Plasma exosomal miRNAs were evaluated for prognosis in an initial set of 44 metastatic renal cell cancer (mRCC) patients by RNA sequencing. Among ∼3.49 million mappable reads per patient, miRNAs accounted for 93.1% of the mapped RNAs. 227 miRNAs with high abundance were selected for survival analysis. Cox regression analysis identified association of 6 miRNAs with overall survival (OS) (P<0.01, False discovery rate (FDR) < 0.3). Five of the associated miRNAs were quantified in an independent follow-up cohort of 65 mRCC patients by TaqMan-based miRNA assays. Kaplan-Meier analysis confirmed the significant OS association of three miRs; miR-let-7i-5p (P=0.018, HR=0.49, 95% CI=0.21-0.84), miR-26a-1-3p (P=0.025, HR=0.43, 95% CI=0.10-0.84) and miR-615-3p (P=0.0007, HR=0.36, 95% CI=0.11-0.54). A multivariate analysis of miR-let-7i-5p with the clinical factor-based Memorial Sloan-Kettering Cancer Center (MSKCC) score improved survival prediction from an area under the curve (AUC) of 0.58 for MSKCC score to an average AUC of 0.64 across 48-month follow-up time. The multivariate model was able to define a high-risk group with median survival of 14 months and low risk group of 39 months (P=0.0002, HR=3.43, 95%CI, 2.73-24.15). Further validation of miRNA-based prognostic biomarkers are needed to improve current clinic-pathologic based prognostic models in patients with mRCC. biomarker; exosomal miRNA; metastatic renal cell cancer; overall survival
33. The Memorial Sloan Kettering Cancer Center (MSKCC) prognostic score is based on clinical parameters. Pubmed The Memorial Sloan Kettering Cancer Center (MSKCC) prognostic score is based on clinical parameters. We analyzed whole blood mRNA expression in metastatic clear cell renal cell carcinoma (mCCRCC) patients and compared it to the MSKCC score for predicting overall survival. In a discovery set of 19 patients with mRCC, we performed whole transcriptome RNA sequencing and selected eighteen candidate genes for further evaluation based on associations with overall survival and statistical significance. In an independent validation of set of 47 patients with mCCRCC, transcript expression of the 18 candidate genes were quantified using a customized NanoString probeset. Cox regression multivariate analysis confirmed that two of the candidate genes were significantly associated with overall survival. Higher expression of BAG1 [hazard ratio (HR) of 0.14, p < 0.0001, 95% confidence interval (CI) 0.04-0.36] and NOP56 (HR 0.13, p < 0.0001, 95% CI 0.05-0.34) were associated with better prognosis. A prognostic model incorporating expression of BAG1 and NOP56 into the MSKCC score improved prognostication significantly over a model using the MSKCC prognostic score only (p < 0.0001). Prognostic value of using whole blood mRNA gene profiling in mCCRCC is feasible and should be prospectively confirmed in larger studies. metastatic renal cell carcinoma; prognostic biomarkers; whole blood mRNA gene expression
34. BACKGROUND: Breast conservation therapy has become a preferred method of treating early-stage breast cancer. Pubmed BACKGROUND: Breast conservation therapy has become a preferred method of treating early-stage breast cancer. As care continues to evolve, certain lesions allowed less invasive treatment options. A simplified explanation of early breast cancer care is detection, biopsy, surgery, and adjuvant therapy. The authors look to challenge that algorithm for a specific type of disease. METHODS: A retrospective review was performed to identify all subcentimeter breast cancer that underwent surgery after core biopsy. These cases (n = 115) were analyzed for biopsy technique and outcome of final surgical excision to find when no residual disease was found on final pathology, potentially rendering the surgical resection an unneeded procedure. RESULTS: The authors found that 17 of 115 patients (14.8%) who underwent biopsy for subcentimeter breast cancer had no residual disease found on final surgical resection. Although the subsets were small, the largest core needle resulted in negative pathology two of three times, while the smallest gauge, never resulted in negative resection at time of surgery. CONCLUSIONS: Nearly, fifteen percent of patients were found to have no residual disease on final surgical pathology. These results were obtained when the radiologist was simply trying to get tissue diagnosis. The authors postulate that this percentage could be even higher if protocols were initiated to biopsy these small lesions with larger core biopsies and possibly alleviate the need for formal surgery in these specific, small lesion. Copyright © 2017 Elsevier Inc. All rights reserved.

3D Tissue Models
About Us | Privacy Policy | Site Map | FAQs | Advertise With Us | Community promotes research and ranks life scientists working in the life science spectrum involving biotechnology,
drug discovery, genomics, microbiology, neuroscience, medicine, pharmacology, cell biology, and molecular biology.